Effectiveness of micronized progesterone for the prevention of miscarriage


如何引用文章

详细

The data on the efficacy of micronized progesterone (Prajisun) for the prevention of miscarriage in women with a obstetric and gynecological history. Materials and methods. The study involved 56 women aged 19-38 years at 4-14 weeks of pregnancy, of which the main group of 30 were: infertility in anamnesis - 17 thrombophilic states against the background of the centers of urogenital infection - 7, uterine malformations - 6 pregnant. A control group comprised 26 healthy women without a history of complications during current pregnancy. All patients have gone through the physical examination, including the definition of the parameters of hemostasis D-dimer, AIII, protein C and S. In the study, blood levels of progesterone, interleukin-1b, interferon-y before and after treatment with micronized progesterone. Changes in the hemostatic system is also evaluated in the dynamics of observation and treatment.The results of the study. Among women, in the main group lower levels of progesterone in the blood were found, with the most pronounced case being retrochorial hematoma. The threat of abortion directly correlated with the level of progesterone and content of proinflammatory cytokines in the blood, the values of which are several times higher than health indicators: , interleukin-1b - 5, interferon-y - 3,7 times. Against the background of treatment with 400 mg Prajisun vaginally within two weeks there was a significant decline in pro-inflammatory cytokines, increased progesterone levels, normal levels of fibrinogen, D-dimer and spontaneous rate of platelet aggregation. Pregnancy progressed successfully in all women.Conclusion. The use of micronized progesterone Prajisun in early pregnancy in women with obstetric and gynecological history pathogenetically substantiated and effective in reducing high risk of miscarriage.

作者简介

L Maltseva

Kazan State Medical Academy of the Ministry of Health of the Russian Federation

Email: laramalc@mail.ru
д-р мед. наук, проф., зав. каф. акушерства и гинекологии ГБОУ ДПО КГМА 420012, Russian Federation, Kazan, ul. Mushtari, d. 11

D Nikogosyan

Republican Clinical Hospital №2. 420043, Russian Federation

Email: diananiko@mail.ru
канд. мед. наук, врач акушерского отд-ния ГАУЗ РКБ №2 Kazan, ul. Chekhova, d. 1a

参考

  1. Dan Farine Международная и европейская школа непрерывного образования в перинатологии, неонатологии и репродуктивной медицине. Preis School - Флоренция, 2013.
  2. Predicting adverse obstetric outcome after early pregnancy events and complications: a review. Hum Reprod Update 2009; 15 (4): 408-21.
  3. Wahabi H.A, Fayed A.A, Esmaeil S.A et al. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev 2011; 12: CD005943.
  4. Рожденные слишком рано. Доклад о глобальных действиях в отношении преждевременных родов. ВОЗ, 2012.
  5. Fonseca E.B, Bittar R.E. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk. AJOG 2003; 188: 419-24.
  6. Ипастова И.Д., Руднева О.Д., Чупурова И.Н. Возможные риски необоснованного назначения препаратов прогестерона во время гестации. Status Praesens. 2014; 8: 67-73.
  7. Мальцева Л.И., Юпатов Е.Ю., Никогосян Д.М. Патогенетическое обоснование терапии угрожающих преждевременных родов. Вопр. гинекол., акуш. и перинатол. 2009; 8 (4): 17-21.

补充文件

附件文件
动作
1. JATS XML

版权所有 © Consilium Medicum, 2015

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).